NCT01538641View on ClinicalTrials.gov

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

August 31, 2007

Study Completion Date

December 31, 2008

Conditions
Refractory Aggressive Non-Hodgkin's LymphomaRelapsing Aggressive Non-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab, Gemcitabine, Oxaliplatin

Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.

All Listed Sponsors
lead

Auxilio Mutuo Cancer Center

OTHER

NCT01538641 - Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas | Biotech Hunter | Biotech Hunter